Anne S. Tsao, MD, and Edward B. Garon, MD, MS, conclude their discussion with a look to the future of TROP2 and associated targeted therapy approaches in non–small cell lung cancer.
Exploring the Perioperative Treatment Setting in Lung Cancer
An expert addressed the emerging role of immune checkpoint inhibitors in the perioperative space based on findings from the CheckMate 816, IMpower010, PEARLS, and ADAURA trials.
Read More
Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care
In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.
Listen
POLESTAR Results Show PFS Benefit of Aumolertinib in NSCLC
Aumolertinib improved progression-free survival vs placebo in patients with unresectable stage III non–small cell lung cancer, according to data from an interim analysis of the phase 3 POLESTAR trial.
Strategies for Neoadjuvant NSCLC Treatment
In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.
Pembrolizumab/Chemo Continues to Impress in NSCLC With 5-Year Updates
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung cancer setting in the second article of a 2-part series.
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors or docetaxel in patients with metastatic non–small cell lung cancer.